E Nunn, N Jaiswal, M Gavin, K Uehara, M Stefkovich, K Drareni, R Calhoun, M Lee, C Holman, J Baur, S Patrick, P. Titchenell. Antibody Blockade of Activin Type II Receptors Preserves Skeletal Muscle ...

Versanis’ main asset is bimagrumab, a monoclonal antibody that binds to the activin type II receptor on skeletal muscle and was originally developed by Novartis for muscle-wasting diseases ...

Loss-of-function ALK7 variants have been associated with improved body composition, protection from type 2 diabetes ... to reduce the production of Activin receptor-like kinase 7 (ALK7), which ...